$HYFT What makes the MindWalk story so interesting is that it's the underdog in a space dominated by companies that have raised hundreds of millions, and in some cases billions, of dollars.
The AI drug discovery sector is filled with well-funded companies, impressive presentations, and massive partnerships. Yet many are still trying to prove that their technology can consistently translate computational predictions into meaningful biological outcomes.
Meanwhile, MindWalk has operated with a fraction of the capital and attention, yet continues to move programs forward while building a biological knowledge base that has been accumulating for years.
The market tends to assume the biggest budgets will win. History says that's not always true.
Sometimes the winner is the company that quietly spends years building the foundation while everyone else is focused on marketing the vision.
The next chapter for MindWalk won't be determined by how much money competitors have raised. It will be determined by whether the science continues to validate.
For a company of this size, that's a pretty interesting position to be in.
@Bulvarpress Bravo, vous pourrez bâtir davantage qu'une seule maison avec autant de bois. Cet arbre aurait dû être coupé beaucoup plus tôt parcontre. Pourquoi attendre 1500 ans ?
#BigRigAlert 🚨 $HYFT @ImmunoPrecise @BioStrandBV#LensAI™ MindWalk with a bit of a shaky start to the rebrand but earning call Monday and share price finding its legs here now. BigRig bold prediction is we see $3-$5 in October… Last at $2.29 #MindWalk https://t.co/XHYSChYGrg